Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations.

Transformation to accelerated phase or blast phase while on the study was lower on the bosutinib arm (2% versus 4%); however, this did not reach statistical significance. 45 Some experts feel the reason this trial failed to meet its primary end point is because of the high rate of bosutinib discontinuation in the BELA study (19% on bosutinib versus 6% on imatinib); however, it is possible that there are multiple factors that contributed to this finding, including lack of experience on the part of some investigators in dealing with the early side effects of the drug.

also in 111,027 other papers